ClinVar Miner

Submissions for variant NM_000155.4(GALT):c.442C>T (p.Arg148Trp) (rs111033693)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000414362 SCV000110061 pathogenic not provided 2018-05-16 criteria provided, single submitter clinical testing
GeneDx RCV000414362 SCV000491247 pathogenic not provided 2016-10-27 criteria provided, single submitter clinical testing The R148W missense variant in the GALT gene has been previously reported in patients with galactoemia (Reichardt et al. 1992; Berry et al. 2000; Bosch et al. 2005). Expression of R148W in COS cells found that it is associated with no detectable galactose-1-phosphate uridyltransferase enzyme activity (Reichardt et al. 1992). The R148W variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. R148W is a non-conservative amino acid substitution, it occurs at a position that is conserved in mammals, and in silico analysis predicts this variant is probably damaging to the protein structure/function. Furthermore, multiple missense variants at the same position (R148Q, R148G) and in nearby residues (S143L, V150L, V151A) are interpreted to be pathogenic variants associated with galactosemia, supporting the functional importance of this region of the protein. In summary, we interpret R148W to be a pathogenic variant.
Integrated Genetics/Laboratory Corporation of America RCV000022113 SCV000919399 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2018-01-23 criteria provided, single submitter clinical testing Variant summary: The GALT c.442C>T (p.Arg148Trp) variant involves the alteration of a conserved nucleotide. 3/3 in silico tools predict a damaging outcome for this variant. This variant was found in 9/277232 control chromosomes at a frequency of 0.0000325, which does not exceed the estimated maximal expected allele frequency of a pathogenic GALT variant (0.0028868). The variant has been reported in affected individuals in the literature (Berry_2000; Bosch_2005; (Reichardt_1992; Schadewaldt_2014). A functional studies showed the variant to result in nondetectable levels of immunoreactive protein, despite normal levels of mRNA signifying unstable protein (Reichardt_1992; Schadewaldt_2014). Other variants affecting the same codon have been reported as pathogenic [c.442C>G (p.Arg148Gly), c.443G>A (p.Arg148Gly)], further supporting the functional importance of the position. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic.
Research and Development, ARUP Laboratories RCV000022113 SCV000042791 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2012-12-04 no assertion criteria provided clinical testing Converted during submission to Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.